Medidata Study Experience

  1. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  2. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.

  3. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.

  4. Synthetic Control Arm In Clinical Trials 12/8/2022

    Get an overview of the SCA, an external control generated with the goal of improving the interpretation of uncontrolled trials, which can enable better product development decisions.

  5. Glioblastoma Multiforme 11/15/2022

    Medidata AI’s Synthetic Control Arm® (SCA®) leverages historical clinical trial data (HCTD) to provide a more relevant clinical insight for the purpose of developing new therapies.

  6. Data-Powered Financial Management For Your Clinical Trials 10/20/2022

    Achieve complete financial visibility, eliminate complexity, and ensure the financial health of your clinical trials with Rave Clinical Trial Financial Management.

  7. Improving Diversity In Clinical Trials 10/17/2022

    Watch how building on your existing feasibility processes and selecting countries and sites that can not only help you accelerate your study, but also increase diversity. 

  8. Reducing Uncertainty: AI & Data Can Help Fuel New Ways Of Working On Clinical Trials & Beyond 10/6/2022

    In this podcast, explore how artificial intelligence and data can help fuel new ways of working on clinical trials and beyond, and the benefits are clear in the heavily regulated industry.

  9. Predictors Of Severe CRS In Longitudinal CAR T-Cell Clinical Trial Data 9/15/2022

    Find out how laboratory tests were analyzed with repeated measurements to identify differences in trends that persist across a variety of study designs, sponsors, and indications.

  10. Solving The Impossible In Glioblastoma With An AI Synthetic Control Arm 9/9/2022

    This video discusses Medicenna’s MDNA55-05 clinical trial; a single-arm, open-label, multicenter study that offers a promising opportunity to improve outcomes for recurrent glioblastoma.